New Delhi: With Russia’s latest tie-up with Dr Reddy Laboratories Ltd, the final stage clinical trials of the world’s first potential coronavirus vaccine – Sputnik V – could begin in India in the next few weeks.Also Read - Assam Tightens COVID Curbs, Non-Vaccinated People Banned From Visiting Public Places
The COVID antidote, that has been developed by Russian Direct Investment Fund, is set to enroll at least 1,000 to 1,200 participants for the late-stage trials at multiple government and private hospitals across the country, officials at the drugmaker firm said. Also Read - Budget Session 2022: Covid Rules To Be Implemented Again, President's Address On January 31
“We want to get to the first step – which is the commencement of the clinical trials by getting the necessary approvals from the Indian regulators – within the next few weeks,” Deepak Sapra, CEO for API and pharmaceutical services at Dr Reddy’s told Reuters. Also Read - As Omicron Situation Gets Better in UK, PM Boris Johnson Lifts Covid-19 Testing For Fully Vaccinated Travellers
Notably, once approved, Russia is expected to supply 100 million doses of the coronavirus vaccine to India. Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India, said the Russian fund had stated.
Sputnik V, an adenovirus vector-based vaccine, was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund and registered on August 11.